PTO/SB/21 (09-04)

Approved for use through 07/31/2006. OMB 0651-0031 rademark Office: U.S. DEPARTMENT OF COMMERCE

| ONE | i | Application Numbe | ar | 10/621,229 |
|---|------------------|--|-------------|---|
| TRANSMITTAL | - | Filing Date | | July 15, 2003 |
| MAY 0 6 2005 FORM | | First Named Invent | itor | Legarda Ibanez |
| . # | | Art Unit | | 1614 |
| To larged for all correspondence after in | initial filing) | Examiner Name | | Jennifer Kim |
| Total Number of Pages in This Submissi | | Attorney Docket No | umber | 55979/314589 |
| | ENCLO | OSURES (check all tha | at apply) | |
| Fee Transmittal Form | ☐ Drawing(s | | | After Allowance Communication to TC |
| Fee Attached | Licensinç | g-related Papers | J | Appeal Communication to Board |
| Amendment / Reply | Petition | | | of Appeals and Interferences Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) |
| After Final | | o Convert to a | 1 | Proprietary Information |
| Affidavits/declaration(s) | Power of | Attorney, Revocation of Correspondence Add | Iress | Status Letter |
| Extension of Time Request | Terminal | Disclaimer | | Other Enclosure(s) (please identify below): |
| - Abandanment Request | Request | for Refund | 1 | PTO/SB/21 transmittal form |
| Express Abandonment Request | CD, Num | nber of CD(s) | ļ | return postcard |
| ☐ Information Disclosure Statement | Lar | ndscape Table on CD | | |
| Certified Copy of Priority Document(s) | Remarks | | | |
| Reply to Missing Parts/ | | | | |
| Incomplete Application | | | * | |
| Reply to Missing Parts under 37 CFR1.52 or 1.53 | | | | |
| SIGI | NATURE OF | APPLICANT, ATTOR | RNEY, O | R AGENT |
| Firm | Kilpatrick Stock | | | |
| Signature | Kustin | rall | | |
| Printed Name | Kristin M. Crall | | | |
| Date | May 4, 2005 | | Reg. No. | 46,895 |
| | CERTIFICA | ATE OF TRANSMISS | ION/MAI | ILING |
| | rst class mail i | in an envelope addres | | O or deposited with the United States Post Commissioner for Patents, P.O. Box 1450 |
| // | de Wha | The state of the s | | |
| 1 / / / / / | M DUTON | M . | | |

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Date

May 4, 2005

Sandee Whitley

Typed or printed name



Attorney Docket No. 55979/314589 (0100US)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:

LEGARDA IBANEZ

Serial No.:

10/621,229

Group Art Unit:

1614

Filed:

July 15, 2003

Examiner:

Jennifer Kim

For:

USE OF FLUMAZENIL IN THE PRODUCTION OF A DRUG FOR THE

TREATMENT OF ALCOHOL DEPENDENCY

Commissioner for Patents P. O. Box 1450 Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Rules 56, 97, and 98 of the Rules of Practice in Patent Cases (37 C.F.R. §§ 1.56, 1.97, and 1.98), the publications listed on the modified Form PTO/SB/08A are enclosed with this submission for consideration by the Examiner.

Submission of the references provided in this Information Disclosure Statement is not intended to constitute an admission that any reference referred to herein is prior art for this invention unless specifically designated as such. Also, in accordance with 37 C.F.R. § 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that an exhaustive search has been made or that no other material information as defined in

CERTIFICATE OF MAILING (37 CFR 1.8a)

I hereby certify that this correspondence, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on this ______ day of May, 2005, with sufficient postage as first-class mail in an envelope addressed to Commissioner for Patents, P. O. Box 1459, Alexandria, VA 22313-1450.

Sandee Whitley

ATLLIB01 1986807.1

U.S.S.N.: 10/621,229 INFORMATION DISCLOSURE STATEMENT

37 C.F.R. § 1.56(a) exists.

This Information Disclosure Statement is being filed before the issuance of a first office action on the merits of the application (37 C.F.R. 1.97(b)(3)); therefore, no fee is believed to be due. If a fee is due, the Commissioner is authorized to charge such fee and any additional fees that may be due or credit any overpayment to Deposit Account No. 11-0855.

Respectfully submitted,

Kustin Crall

Kristin Mallatt Crall

Registration No. 46,895

Date: May 4, 2005

KILPATRICK STOCKTON LLP Suite 2800, 1100 Peachtree Street Atlanta, Georgia 30309-4530 (404) 815-6147

PTO/SB/08a (08-03)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE

STATEMENT BY APPLICANT

Application Number

Filing Date

First Named Inventor

(Use as many sheets as necessary)

of

Sheet

| | Complete if Known | , |
|------------------------|-----------------------|---|
| Application Number | 10/621,229 | |
| Filing Date | July 15, 2003 | |
| First Named Inventor | Legarda Ibanez | |
| Art Unit | 1614 | |
| Examiner Name | Jennifer Kim | |
| Attorney Docket Number | 55979/314589 (0100US) | |

| | | | U.S. PATENT D | OCUMENTS | |
|------------------------|--------------|--|--------------------------------|--|---|
| Examiner Initials * | Cite No.1 | Document Number | Publication Date MM-DD-YYYY | Name of Patentee or Applicant of Cited Document | Pages, Columns, Lines, Where Relevant Passages or Relevant |
| iinuais | 1,40. | Number - Kind Code ² (if known) | IVIAVI-DD-1111 | | Fassages of Relevant |
| | <u> </u> | US- | | | |
| | | US- | • | | |
| | | US- | | | |
| | | US- | | | |
| | | US- | | | 100 110 |
| | | US- | | | |

| | | FOREIGN PA | TENT DOCU | MENTS | | |
|-----------|------|--|--------------------|--------------------------------|--|----------------|
| Examiner | Cite | Foreign Patent Document | Publication | Name of Patentee or | Pages, Columns, Lines, Where Relevant | |
| Initials* | No.1 | Country Code ³ - Number ⁴ - Kind Code ⁵ (<i>if known</i>) | Date MM-DD-YYYY | Applicant of Cited Document | Passages or Relevant Figures Appear | Τ ⁶ |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| | | | | | | |
| I | | | | | | |

| Examiner Signature | Date Considered | |
|-----------------------|--------------------|--|

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁵ Applicant is to place a check mark here if English language Translation is attached.

Traistation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

| | Substitute | for form 1449 | В/РТО | | | | Complete if Known |
|---------------|------------|---------------|-----------|----------|-----------|------------------------|-----------------------|
| | INIEO | DRAATI | 0N DI | <u>.</u> | OL OCUPE | Application Number | 10/621,229 |
| | | | | | CLOSURE | Filing Date | July 15, 2003 |
| | STAT | EMEN | I BY | ٩F | PPLICANT | First Named Inventor | Legarda Ibanez |
| | | | | | | Art Unit | 1614 |
| | | (Use as mar | ny sheets | as n | ecessary) | Examiner Name | Jennifer Kim |
| $\overline{}$ | Sheet | 2 | 0 | f | 2 | Attorney Docket Number | 55979/314589 (0100US) |

| | | NON PATENT LITERATURE DOCUMENTS | γ |
|---------------------|--------------|---|--------------|
| Examiner Initials * | Cite No.1 | Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published. | Τ2 |
| | 1 | American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Washington, D.C., American Psychiatric Association, 1994, pp. 194-204. | |
| | 2 | BUCK, K. J., Reversal of Alcohol Dependence and Tolerance by a Single Administration of Flumazenil, The Journal of Pharmacology and Experimental Therapeutics, 1991, Vol. 257, No. 3, pp. 984-989. | |
| | 3 | FILE, S.E., Effects of Nitrendipine, Chlordiazepoxide, Flumazenil and Baclofen on the Increased Anxiety Resulting from Alcohol Withdrawal, Prog. Neuro-Psychopharmacol & Biol. Psychiatry, 1992, Vol. 16, No. 1, pp. 87-93. | |
| | 4 | GERRA, G., Effectiveness of Flumazenil in the Treatment of Ethanol Withdrawal, Current Therapeutic Research, July 1991, Vol. 50, No. 1, pp. 62-66. | |
| | 5 | NUTT, D., Benzodiazepine Receptors in Alcohol Withdrawal Neuroschychopharmacology, May 1994, Vol. 10, No. 35, Part 1. | |
| | 6 | NUTT, D., Flumazenil in Alcohol Withdrawal, Alcohol & Alcoholism, 1992, Suppl. 2, pp. 337-341. | |
| | 7 | POTOKAR, J., Flumazenil in Alcohol Withdrawal: a Double-blind Placebo-controlled Study, Alcohol & Alcoholism, 1997, Vol. 32, No. 5, pp. 605-611. | |
| | 8 | Practice Management Information Corporation: International Classification of Diseases, 9 th Revision, Clinical Modification, Sixth Edition (ICD-9-CM), 2004, selected pages. | |
| | | | |
| | | | |
| | | | |

| | · · · · · · · · · · · · · · · · · · · | | |
|-----------|---------------------------------------|------------|--|
| Examiner | | Date | |
| Signature | | Considered | |

^{*}EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance

and not considered. Include copy of this form with next communication to applicant.

Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 120 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.